These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 4342570)

  • 21. The development of the acid phosphatase test for prostatic carcinoma: the Sixth Ferdinand C. Valentine Memorial Lecture.
    Gutman AB
    Bull N Y Acad Med; 1968 Jan; 44(1):63-76. PubMed ID: 5239152
    [No Abstract]   [Full Text] [Related]  

  • 22. Ectonucleotide pyrophosphatase/phosphodiesterase (E-NPP) and adenosine deaminase (ADA) activities in prostate cancer patients: influence of Gleason score, treatment and bone metastasis.
    Battisti V; Maders LD; Bagatini MD; Battisti IE; Bellé LP; Santos KF; Maldonado PA; Thomé GR; Schetinger MR; Morsch VM
    Biomed Pharmacother; 2013 Apr; 67(3):203-8. PubMed ID: 23433854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostatic serum acid phosphatase as an aid in the diagnosis of prostatic carcinoma; preliminary report.
    BAURYS W; WENTZELL RA
    Guthrie Clin Bull; 1956 Oct; 26(2):72-6. PubMed ID: 13397847
    [No Abstract]   [Full Text] [Related]  

  • 24. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
    Jung K; Laube C; Lein M; Türk I; Lichtinghagen R; Rudolph B; Schnorr D; Loening SA
    Int J Cancer; 1998 Oct; 78(3):392-3. PubMed ID: 9766579
    [No Abstract]   [Full Text] [Related]  

  • 25. Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
    Blackard CE; Byar DP; Seal US; Doe RP
    J Urol; 1975 Apr; 113(4):517-20. PubMed ID: 163929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estramustine versus conventional estrogenic hormones in the initial treatment of highly or moderately differentiated prostatic carcinoma. A randomized study.
    Andersson L; Berlin T; Boman J; Collste L; Edsmyr F; Esposti PL; Gustafsson H; Hedlund PO; Hultgren L; Leander G; Nordle O; Norlén H; Tillegård P
    Scand J Urol Nephrol Suppl; 1980; 55():143-5. PubMed ID: 6259722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Phosphatases in pleural effusions of various character. Their significance in cancer of the prostate].
    Véran P; Moigneteau C; Lasausse G; Bernard S; Lanta M
    J Fr Med Chir Thorac; 1965; 19(6):621-43. PubMed ID: 4285004
    [No Abstract]   [Full Text] [Related]  

  • 28. [Clinical significance of an increase in the serum acid phosphatase].
    Mischol HR
    Dtsch Med Wochenschr; 1970 Aug; 95(32):1653-4. PubMed ID: 5433403
    [No Abstract]   [Full Text] [Related]  

  • 29. [The significance of enzyme diagnosis for the general practitioner].
    Amelung D
    Hippokrates; 1969 May; 40(10):371-7. PubMed ID: 4308539
    [No Abstract]   [Full Text] [Related]  

  • 30. [Acid and alkaline blood phosphatase and diagnosis of prostate carcinoma].
    VAN DEN HOOFF A; SMITS G
    Ned Tijdschr Geneeskd; 1955 Apr; 99(14):1026-9. PubMed ID: 14383826
    [No Abstract]   [Full Text] [Related]  

  • 31. Estracyt (NSC 89199) as a substrate for phosphatases in human serum.
    Tritsch GL; Shukla SK; Mittelman A; Murphy GP
    Invest Urol; 1974 Jul; 12(1):38-9. PubMed ID: 4366126
    [No Abstract]   [Full Text] [Related]  

  • 32. Serum enzyme activity in bone tumors and osteomyelitis (LDH, GOT, GPT, CPK, CHE, ALP, AP, PP, ALD).
    Brozmanová E; Skrovina B
    Neoplasma; 1977; 24(1):109-17. PubMed ID: 190548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Further studies in detection and diagnosis of prostatic carcinoma.
    CLINE JK; BURKE LS; COBB WR; WILKINSON MA; JOHNSON RB
    J Urol; 1955 Feb; 73(2):384-92. PubMed ID: 13234131
    [No Abstract]   [Full Text] [Related]  

  • 34. Histochemical changes of phosphatases in the prostatic gland.
    Aso Y; Hoshino Y; Okada K; Murahashi I; Takayasu H
    Invest Urol; 1968 Nov; 6(3):304-14. PubMed ID: 4177079
    [No Abstract]   [Full Text] [Related]  

  • 35. [Value of determination of phosphatases in determination of prostatic cancer].
    WOJEWSKI A
    Urol Pol; 1956; 9():35-42. PubMed ID: 13401602
    [No Abstract]   [Full Text] [Related]  

  • 36. Alkaline and acid phosphatase determinations in bone disease.
    Van Lente F
    Orthop Clin North Am; 1979 Apr; 10(2):437-50. PubMed ID: 36589
    [No Abstract]   [Full Text] [Related]  

  • 37. [Bone fractions of alkaline phosphatase in prostatic cancer with bone metastasis].
    Larach G; Rodrigo C; Schwartzmann R
    Rev Med Chil; 1984 Aug; 112(8):802-5. PubMed ID: 6543473
    [No Abstract]   [Full Text] [Related]  

  • 38. Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma?
    Kirchheimer JC; Binder BR; Pflueger H; Hienert G
    Thromb Haemost; 1985 Oct; 54(3):729. PubMed ID: 4089804
    [No Abstract]   [Full Text] [Related]  

  • 39. Some factors other than neoplasms altering the prostatic fraction of acid phosphatase in the serum.
    BONNER CD; HOMBURGER F; FISHMAN WH
    Surg Gynecol Obstet; 1954 Aug; 99(2):179-83. PubMed ID: 13187197
    [No Abstract]   [Full Text] [Related]  

  • 40. The value of combined blood phosphatase and sedimentation rate determinations in the diagnosis of metastasis in prostatic carcinoma.
    BOYLAN RN; TILLISCH JH
    J Urol; 1948 May; 59(5):931-4. PubMed ID: 18913856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.